Cancer Screening Has Provided Significant Value to U.S. Population
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 22, 2023 -- Cancer screening has provided significant value to the U.S. population, and improved adherence would add more value, according to a study published online Aug. 7 in BMC Health Services Research.
Tomas J. Philipson, Ph.D., from the University of Chicago, and colleagues built a mathematical model to estimate the aggregate benefits of screenings for breast, colorectal, cervical, and lung cancer over time using U.S. census data. The full potential benefits with perfect adherence and the benefits considering reported adherence were estimated for each screening type.
The researchers found that up to 417 million people were eligible for cancer screening since the initial U.S. Preventive Services Task Force (USPSTF) recommendations. The life-years gained from screenings were estimated to be 15.5 to 21.3 million assuming perfect adherence to recommendations (2.2 to 4.9, 1.4 to 3.6, 11.4 to 12.3, and 0.5 million for breast, colorectal, cervical, and lung cancer, respectively). Combined screening has saved 12.2 to 16.2 million life-years at reported adherence rates since the introduction of the USPSTF recommendations. These benefits represent a value of $8.2 to $11.3 trillion at full potential and $6.5 to $8.6 trillion at current adherence levels. With perfect adherence, single-site screenings could save an additional 3.2 to 5.1 million life-years, representing $1.7 to $2.7 trillion.
"Single-site cancer screenings have offered significant cumulative gains to U.S. life-years gained and improvements to value of screening, despite screening adherence leading to a nontrivial gap between full potential and realized benefit considering adherence," the authors write.
Several authors disclosed ties to Grail LLC, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Resistance Exercise Boosts Outcomes After Early-Stage Breast Cancer Surgery
FRIDAY, June 7, 2024 -- Early resistance exercise following surgery for early-stage breast cancer improves shoulder range of motion (ROM) and strength at one month and six months...
ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...
ASCO: Ivonescimab Improves Progression-Free Survival in EGFR+ Lung Cancer
THURSDAY, June 6, 2024 -- For patients with non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant, ivonescimab plus chemotherapy improves...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.